Literature DB >> 29217826

Parkinson's disease - the story of an eponym.

Michel Goedert1, Alastair Compston2.   

Abstract

One of the most prevalent neurodegenerative diseases worldwide is still referred to as 'Parkinson's disease'. The condition is named after James Parkinson who, in 1817, described the shaking palsy (paralysis agitans). In the bicentennial year of this publication, we trace when and why the shaking palsy became Parkinson's disease. The term was coined by William Rutherford Sanders of Edinburgh in 1865 and later entered general usage through the influence of Jean-Martin Charcot and the school that he nurtured at the Salpêtrière Hospital in Paris. Despite a move towards more mechanism-based nosology for many medical conditions in recent years, the Parkinson's disease eponym remains in place, celebrating the life and work of this doctor, palaeontologist and political activist.

Entities:  

Mesh:

Year:  2017        PMID: 29217826     DOI: 10.1038/nrneurol.2017.165

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  14 in total

1.  Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo.

Authors:  Keith A Josephs; Joseph E Parisi; Dennis W Dickson
Journal:  Neurology       Date:  2002-08-27       Impact factor: 9.910

2.  The black stuff and Konstantin Nikolaevich Tretiakoff.

Authors:  Andrew J Lees; Marianna Selikhova; Luiz Augusto Andrade; Charles Duyckaerts
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

3.  Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders.

Authors:  V Buée-Scherrer; L Buée; B Leveugle; D P Perl; P Vermersch; P R Hof; A Delacourte
Journal:  Ann Neurol       Date:  1997-09       Impact factor: 10.422

4.  An essay on the shaking palsy.

Authors:  Andrew Lees
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

5.  Tuesdays at the Salpêtrière. "Charcot the clinician: the Tuesday lessons, excerpts from nine case presentations on general neurology delivered at the Salpêtrière Hospital in 1887-88." By Jean-Martin Charcot. Essay review.

Authors:  T Gelfand
Journal:  Bull Hist Med       Date:  1989       Impact factor: 1.314

6.  The history of Parkinson's disease: early clinical descriptions and neurological therapies.

Authors:  Christopher G Goetz
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

7.  Athetosis.

Authors:  T J Putnam
Journal:  Yale J Biol Med       Date:  1939-05

Review 8.  PINK1 and Parkin: emerging themes in mitochondrial homeostasis.

Authors:  Thomas G McWilliams; Miratul Mk Muqit
Journal:  Curr Opin Cell Biol       Date:  2017-04-22       Impact factor: 8.382

Review 9.  Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.

Authors:  Daniela Berg; Ronald B Postuma; Bastiaan Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda M Halliday; John Hardy; Anthony E Lang; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl
Journal:  Mov Disord       Date:  2014-03-11       Impact factor: 10.338

10.  Parkin disease: a clinicopathologic entity?

Authors:  Karen M Doherty; Laura Silveira-Moriyama; Laura Parkkinen; Daniel G Healy; Michael Farrell; Niccolo E Mencacci; Zeshan Ahmed; Francesca M Brett; John Hardy; Niall Quinn; Timothy J Counihan; Timothy Lynch; Zoe V Fox; Tamas Revesz; Andrew J Lees; Janice L Holton
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

View more
  9 in total

1.  Kir6.2 Deficiency Promotes Mesencephalic Neural Precursor Cell Differentiation via Regulating miR-133b/GDNF in a Parkinson's Disease Mouse Model.

Authors:  Yan Zhou; Jialei Zhu; Yang Lv; Chenghuan Song; Jianhua Ding; Ming Xiao; Ming Lu; Gang Hu
Journal:  Mol Neurobiol       Date:  2018-03-21       Impact factor: 5.590

Review 2.  Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.

Authors:  Richa Tyagi; Bhupesh Vaidya; Shyam Sunder Sharma
Journal:  Pharmacol Rep       Date:  2022-09-23       Impact factor: 3.919

3.  Metformin improves depressive-like behavior in experimental Parkinson's disease by inducing autophagy in the substantia nigra and hippocampus.

Authors:  Ingrid Prata Mendonça; Igor Henrique Rodrigues de Paiva; Eduardo Pereira Duarte-Silva; Michel Gomes de Melo; Rodrigo S da Silva; Maria Isabelly Xavier do Nascimento; Christina Alves Peixoto
Journal:  Inflammopharmacology       Date:  2022-08-06       Impact factor: 5.093

Review 4.  Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification.

Authors:  Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 5.  Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials.

Authors:  Guowang Cheng; Yujing Liu; Rui Ma; Guopan Cheng; Yucheng Guan; Xiaojia Chen; Zhenfeng Wu; Tongkai Chen
Journal:  Nanomicro Lett       Date:  2022-04-15

6.  Pierre D. and the first photographs of Parkinson's disease.

Authors:  Patrick A Lewis; Helene Plun-Favreau; Mark Rowley; Jennifer Spillane
Journal:  Mov Disord       Date:  2020-01-24       Impact factor: 10.338

7.  Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson's Disease.

Authors:  Shanshan Hu; Meigui Hu; Jian Liu; Bei Zhang; Zhen Zhang; Fiona H Zhou; Liping Wang; Jianghui Dong
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-04       Impact factor: 2.570

8.  The loss of dopaminergic neurons in DEC1 deficient mice potentially involves the decrease of PI3K/Akt/GSK3β signaling.

Authors:  Zhu Zhu; Wu Yichen; Zhang Ziheng; Ge Dinghao; Lu Ming; Liu Wei; Shan Enfang; Hu Gang; Hiroaki Honda; Yang Jian
Journal:  Aging (Albany NY)       Date:  2019-12-28       Impact factor: 5.682

Review 9.  Invited Review: The role of prion-like mechanisms in neurodegenerative diseases.

Authors:  Z Jaunmuktane; S Brandner
Journal:  Neuropathol Appl Neurobiol       Date:  2020-02-11       Impact factor: 8.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.